Payment overview · 2025
General Payments
$392.91
21 reported records · 12 companies
Healthcare provider profile · identity verified
Aleobe Eruemulor, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LITTLE ROCK, AR · NPI 1538555248
Verified facts
What the public records show
CMS Open Payments records show Aleobe Eruemulor, M.D. received $392.91 in general payments during 2025 across 21 reported records.
ABBVIE INC. accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.79 | 17.2% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $67.53 | 17.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.72 | 10.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.82 | 10.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.59 | 7.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.22 | 6.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.74 | 6.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.79 | 5.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.86 | 5.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.78 | 5.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.27 | 4.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.80 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $392.91 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $67.79 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $67.53 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.53 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.72 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.72 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.82 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.22 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 100 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
100 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 499 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 437 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 374 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 301 | 79 |
| Omeprazole | Omeprazole | 296 | 82 |
| Lisinopril | Lisinopril | 280 | 70 |
| Losartan Potassium | Losartan Potassium | 253 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 56 |
| Gabapentin | Gabapentin | 247 | 64 |
| Simvastatin | Simvastatin | 201 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 195 | 49 |
| Trazodone Hcl | Trazodone Hcl | 189 | 42 |
| Potassium Chloride | Potassium Chloride | 188 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 47 |
| Metformin Hcl | Metformin Hcl | 168 | 47 |
| Tramadol Hcl | Tramadol Hcl | 160 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 149 | 24 |
| Furosemide | Furosemide | 148 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 19 |
| Mounjaro | Tirzepatide | 100 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 20 |
| Sertraline Hcl | Sertraline Hcl | 93 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 92 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 19 |
| Famotidine | Famotidine | 84 | 22 |
| Mirtazapine | Mirtazapine | 83 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 78 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 21 |
| Carvedilol | Carvedilol | 74 | 17 |
| Alprazolam | Alprazolam | 73 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 28 |
| Nifedipine Er | Nifedipine | 69 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 19 |
| Buspirone Hcl | Buspirone Hcl | 67 | 16 |
| Eliquis | Apixaban | 66 | 14 |
| Glipizide | Glipizide | 65 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 20 |
| Januvia | Sitagliptin Phosphate | 60 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | suppressed |
| Meloxicam | Meloxicam | 55 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 13 |
| Glipizide Er | Glipizide | 52 | 16 |
| Allopurinol | Allopurinol | 51 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 12 |
| Farxiga | Dapagliflozin Propanediol | 51 | suppressed |
| Finasteride | Finasteride | 50 | 14 |
| Prednisone | Prednisone | 50 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 12 |
| Atenolol | Atenolol | 49 | 14 |
| Ozempic | Semaglutide | 49 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 42 |
| Bupropion Xl | Bupropion Hcl | 46 | 14 |
| Montelukast Sodium | Montelukast Sodium | 46 | suppressed |
| Clonazepam | Clonazepam | 45 | suppressed |
| Estradiol | Estradiol | 44 | suppressed |
| Jardiance | Empagliflozin | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 15 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 33 |
| Fluconazole | Fluconazole | 32 | 19 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 24 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 17 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 11 |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Pregabalin | Pregabalin | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Probenecid | Probenecid | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Mupirocin | Mupirocin | 15 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | 14 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $392.91 · 21 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, FREESTYLE LIBRE 3, MOUNJARO, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, Veozah, WATCHMAN FLX, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error